Investments in Variable Interest Entities (Details) - USD ($) $ in Millions |
1 Months Ended | |||
---|---|---|---|---|
May 31, 2018 |
Oct. 31, 2017 |
Mar. 31, 2020 |
Dec. 31, 2019 |
|
Variable Interest Entity [Line Items] | ||||
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities | $ 22.7 | $ 22.7 | ||
Neurimmune | ||||
Variable Interest Entity [Line Items] | ||||
Payments to Noncontrolling Interests | $ 50.0 | $ 150.0 | ||
Reduction in royalty rate payable on commercial sales | 15.00% | |||
Additional reduction in royalty rate payable on commercial sales | 5.00% | |||
Regulatory Milestones [Member] | Neurimmune | ||||
Variable Interest Entity [Line Items] | ||||
Potential Future Milestone Payments Commitment To Third Party Approximately | 75.0 | |||
Regulatory Approval Milestone [Member] | Neurimmune | ||||
Variable Interest Entity [Line Items] | ||||
Potential Future Milestone Payments Commitment To Third Party Approximately | $ 100.0 |